19 results about "Platlet-Derived Growth Factor" patented technology

The invention belongs to the technical field of medical biomaterial engineering application, and particularly relates to a bone repair scaffold for promoting diabetic bone defect repair. The stent main body is provided with a functional material, and the functional material comprises one or a combination of more than two of the following components: platelet-derived growth factors, copper ions and strontium ions; the weight part ratio of the platelet-derived growth factor to the copper ions to the strontium ions is (0.001-0.1): (0.005-1): (0.01-10). According to the bone repair scaffold provided by the invention, through the synergistic effect of the platelet-derived growth factor (PDGF-BB) and trace metal copper and strontium, the bone defect and osteoporotic bone defect of a diabetic patient are treated.

The present invention relates to improved platelet-derived growth factor (PDGF) polypeptide variants, particularly polypeptides comprising the sequence of any one of SEQ ID NOs: 2 to 4 or a sequence having at least 80% similarity thereto, wherein the PDGF polypeptide exhibits increased stability, biological activity and / or solubility compared to the wild-type PDGF polypeptide of SEQ ID NO: 1. The present invention further provides nucleic acid sequences encoding the PDGF polypeptides of the present invention, and also provides a method for growing animal cells, comprising culturing the animal cells in a culture medium containing the PDGF polypeptide of the present invention.

The invention discloses a serum substitute compatible umbilical cord mesenchymal stem cell culture medium additive composition and application thereof. The serum substitute compatible umbilical cord mesenchymal stem cell culture medium additive composition is prepared from the following components in parts by mass: 15 to 25 parts of platelet-derived growth factor-BB; 15 to 25 parts of basic fibroblast growth factors; 8 to 12 parts of transforming growth factor-beta; and 8-12 parts of recombinant human insulin. The serum substitute compatible umbilical cord mesenchymal stem cell culture medium additive composition and the application thereof disclosed by the invention have the following beneficial effects: (1) the proliferation efficiency is remarkably improved; (2) the cell morphology and dryness can be well maintained; and (3) the compliance and the compatibility are good.

The present application relates to the technical field of freeze-dried powder, and in particular to a freeze-dried powder composition for hair regeneration and a preparation method thereof. The freeze-dried powder composition comprises 5-15 parts of vascular endothelial growth factor, 3-10 parts of platelet-derived growth factor, 1-5 parts of copper peptide, 0.5-3 parts of acetyl tetrapeptide-3, 2-8 parts of baicalein, 1-5 parts of asiaticoside, 20-40 parts of freeze-drying protectant, and 1-3 parts of nano-silicon dioxide. The preparation method comprises mixing the pretreated vascular endothelial growth factor, platelet-derived growth factor, copper peptide, acetyl tetrapeptide-3, baicalein, and asiaticoside with the freeze-drying protectant and nano-silicon dioxide, and then freeze-drying. The freeze-dried powder composition can promote the growth of hair, improve the microenvironment of the scalp, and provide long-lasting support for the healthy growth of hair. The preparation method improves the stability and biological activity of the active ingredients, and enhances the overall performance and safety of the product.

Modified platelet-derived growth factor receptor alpha (PDGFRα) polypeptides are described. The modified polypeptides include at least one amino acid substitution that allows the polypeptide to retain the capacity to bind a cytomegalovirus (CMV) trimer comprised of glycoprotein H (gH), gL and gO, but leads to reduced binding to one or more platelet-derived growth factor (PDGF) ligands. Use of the modified PDGFRα polypeptides for inhibiting CMV replication and / or spread, or treating a CMV infection, is also described.

This invention discloses a topical preparation of recombinant platelet-derived growth factor (PDGF) and its preparation method. In this invention, each milliliter of the topical preparation contains the following components and dosages: 40,000-85,000 IU of PDGF, 50-200 mg of polyvinyl alcohol, 10-100 mg of arginine hydrochloride, 54-60 mg of sodium chloride, 40-80 mg of disodium hydrogen phosphate, 0.5-2.5 mg of sodium dihydrogen phosphate, and 0.5-5 mg of benzalkonium chloride, diluted to 10 ml with water for injection. The pH of the solution is 7.0. The PDGF topical solution of this invention has optimized compatibility of its raw materials, exhibits good stability, and can promote wound healing effectively and rapidly, shortening wound healing time and improving wound healing efficiency, thus demonstrating good therapeutic efficacy.

The invention discloses a recombinant platelet-derived growth factor gel. The prescription is optimized in multiple dimensions by reducing the types of auxiliary materials of the gel, adjusting a buffer system, the concentration of salt ions and the ratio of the gel matrix to the recombinant human growth factor, so that the adhesion capacity of the gel on the skin is improved, the stability of the gel is improved, the biological activity stability is ensured, and the bioavailability of the gel is improved. Meanwhile, due to the reduction of the auxiliary materials, the production cost and the quality control difficulty are reduced, and the risk of preparation impurities is reduced.

The present disclosure provides methods for treating delayed union or nonunion fractures in a bone More specifically, the present disclosure provides methods of inducing bone formation in a delayed union or nonunion fracture in a bone comprising: applying to a site of delayed union or nonunion fracture a composition comprising a platelet-derived growth factor (PDGF) solution disposed in a biocompatible matrix.

The invention discloses a thalassemia treatment method based on a stem cell technology and application. The thalassemia treatment method comprises the following steps: collecting a peripheral blood sample of a patient, and carrying out stem cell isolated culture; constructing a nucleic acid aptamer by combining a vascular cell adhesion molecule-1 and a stromal cell-derived factor-1 in a bone marrow microenvironment; connecting a nucleic acid aptamer, a cell adhesion promoting peptide and a stem cell growth factor, and constructing a homing guiding reagent; preparing nano liposome and nano polymer particles; the nucleic acid aptamer is connected to the surfaces of the nano-liposome and the nano-polymer particles, and is grafted with a temperature-responsive material to obtain the nano-carrier with a responsive release function; stem cell growth factors and platelet-derived growth factors are mixed with gelatin microspheres to form a slow release system; the cultured stem cells are mixed with a homing guide reagent, a nano-carrier and a slow release system, and are transplanted into the body of a patient through intramedullary injection. The stem cell homing efficiency can be improved, and the treatment effect on thalassemia is improved.

The invention provides injectable growth factor hydrogel as well as a preparation method and application thereof, and relates to the technical field of medical materials. The injectable growth factor hydrogel is developed by taking glycyrrhizic acid (GA) and dopamine modified hyaluronic acid (HA-DA) as a biological matrix material and taking baicalein A (OA) and a platelet-derived growth factor (PDGF-BB) as bioactive functional components. The invention aims to solve the technical problems of non-lasting growth factor release, difficult hydrogel injection, single endometrial repair effect and the like in the existing treatment method, can promote tissue repair and fertility recovery, and has a remarkable clinical application prospect.

The invention relates to the technical field of biomedical materials, and discloses an intelligent responsive degradable hydrogel, which is characterized by comprising the following components: a base material which is a blend of hyaluronic acid and chitosan and has a total concentration of 2.0%-3.0% w / v; the cross-linking agent is an anti-TNF-alpha monoclonal antibody, and the dosage of the cross-linking agent is 0.8 mu mol / g of the base material; the auxiliary cross-linking agent is genipin with the concentration of 0.1% w / v; the loaded drug is a platelet-derived growth factor, and the drug loading capacity is 100 ng / mg of the hydrogel. The hydrogel can specifically recognize an inflammation signal in a chronic wound high TNF-alpha microenvironment, trigger network degradation and synchronously release a repair promoting medicine, recognition-degradation-administration closed-loop regulation is achieved, and the hydrogel is suitable for diabetic foot ulcer and other hard-to-heal wounds.

The invention discloses an application of PDGF-C (Platelet Derived Growth Factor-C) in muscle injury repair. Research finds that in a CTX model mouse with Pdgf-c knocked out, the number of proliferated muscle satellite cells (Pax7 + Ki67 +) is remarkably smaller than that of wild type mice. Through AAV-mediated PDGF-C overexpression, the number of CTX model mouse muscle stem cells can be significantly increased, the activation level of the muscle stem cells is improved, and the self-renewal ability of the muscle stem cells is enhanced. In addition, PDGF-C overexpression also significantly increases the area of muscle fibers of CTX model mice and improves the regeneration and repair ability of the muscle fibers, thereby promoting the healing of muscle injury and having a therapeutic effect on the disease. In addition, the effect of the PDGF-C on promoting muscle injury repair is obviously higher than that of the PDGF-B. Therefore, the invention provides a new method for the treatment of muscle injury, and a new way is possibly opened up for the treatment of other muscle-related diseases.

To provide an agent effective in promoting production of PDGF-BB, and an agent which, by utilizing the agent, is effective for activation and anti-aging of the skin through stabilization of mesenchymal stem cells in the skin.SOLUTION: A PDGF-BB production promoter, which contains any of wasabi extract, chamomile extract, L-theanine, and hibiscus extract as an effective component, is effective for skin activation and anti-aging through stabilization of mesenchymal stem cells.SELECTED DRAWING: Figure 3

The invention relates to the technical field of cell biology, in particular to a culture medium for inducing blood-derived cells to be transformed into (muscle) fibroblasts as well as an induction method and application of the culture medium. According to the culture medium provided by the invention, growth factors and bioactive substances with proper concentrations are compounded in a basic culture medium; mononuclear macrophage activating cytokines or substances (macrophage colony stimulating factors or phorbol ester) and macrophage to (muscle) fibroblast transformation inducing factors (transforming growth factors-beta and platelet-derived growth factors-BB) are used, and patient tissue does not need to be cut. Human blood-derived cells (peripheral blood mononuclear cells or mononuclear macrophages) can be converted into (muscle) fibroblasts capable of expressing collagen and smooth muscle protein, and the method can be used for scientific research, regenerative medicine or anti-aging treatment.

The use of immune-tolerized fetal stem cell-derived extracellular vesicles as a pharmaceutical composition for hair loss treatment is disclosed. The pharmaceutical composition of immune-tolerized fetal stem cell-derived extracellular vesicles for hair loss treatment contains noggin, sclerostin domain-containing protein 1 (SOSTDC1), fibroblast growth factor-7 (FGF-7), and platelet-derived growth factor-alpha (PDGF-α) to promote the conversion of hair in the catagen phase into hair in the anagen phase.

The application provides a kind of osteochondral repair material and its preparation method and application, belong to the technical field of biomedical materials.The application is prepared hyaluronic acid-collagen with collagen as organic matrix, through the crosslinking reaction mediated by crosslinking agent;Hydroxyapatite is deposited in situ in the self-assembly process of collagen fiber through in vitro biomimetic mineralization technology, and mineralized collagen with different mineralization degrees is prepared;Iterative layered freeze-drying technology is used to construct biomimetic cartilage layer, calcification layer and subchondral layer in turn, and transforming growth factor-beta 3 and platelet-derived growth factor-BB are also loaded by physical adsorption to synergistically promote the repair and regeneration of osteochondral defects.The preparation process of the application is mild and controllable, and the prepared osteochondral repair material has good biocompatibility and intelligent active factor delivery function, and has important application prospect in the field of osteochondral tissue engineering and clinical defect repair.

Disclosed herein are compounds of formula (I) wherein X, L1, and HSA conjugate are as defined herein, methods of preparation thereof, and methods of using thereof for improving cardiac repair, particularly post infarct.

The present application provides a kind of stem cell composition for treating male erectile dysfunction and its preparation method, belong to medical technology field.Magnetic particles loaded with platelet-derived growth factor and matrix metalloproteinase are added to culture medium, amniotic membrane mesenchymal stem cells are activated, and activated amniotic membrane mesenchymal stem cells, paracrine composition and magnetic nutrient particles are obtained by separation, mixed with intercalated sustained-release drug compound and penetration activator and added to temperature-sensitive hydrogel sustained-release system to prepare stem cell composition for treating male erectile dysfunction.The stem cell composition for treating male erectile dysfunction prepared by the present application plays a role through multiple pathways, promotes angiogenesis, improves penile hemodynamics, inhibits smooth muscle cell apoptosis, regulates nerve function, enhances endothelial progenitor cell recruitment, etc., thereby more comprehensively repairing and regenerating damaged penile tissue, and has broad application prospects.

The invention provides a dual VEGF / PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is an extracellular trap segment of a VEGFR (i.e., a segment of the extracellular region of one or more VEGFR receptors that inhibits the binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is an extracellular trap segment of a PDGFR (i.e., a segment of the extracellular region of one or more PDGFRs that inhibits the binding of at least one PDGFR to at least one PDGF). The dual antagonist is preferably conjugated to a half-life extension portion, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet age-related macular degeneration.